Abstract

Lung cancer is one of the most common reasons for cancer-induced mortality across the globe, despite major advancements in the treatment strategies including radiotherapy and chemotherapy. Existing reports suggest that CXCR4 is frequently expressed by malignant tumor and is imperative for vascularization, tumor growth, cell migration, and metastasis pertaining to poor prognosis. In this study, we infer that CXCR4 confers resistance to ionizing radiation (IR) in nonsmall cell lung cancer (NSCLC) cells. Further, on the basis of colony forming ability, one finds that drug-resistant A549/GR cells with improved CXCR4 expression exhibited more resistance to IR than A549 cells evidenced along with a reduction in the formation of γ-H2AX foci after IR. Transfection of shRNA against CXCR4 or treatment of pharmacological inhibitor (AMD3100) both led to sensitization of A549/GR cells towards IR. Conversely, the overexpression of CXCR4 in A549 and H460 cell lines was found to improve clonogenic survival, and reduce the formation of γ-H2AX foci after IR. CXCR4 expression was further correlated with STAT3 activation, and suppression of STAT3 activity with siSTAT3 or a specific inhibitor (WP1066) significantly stymied the colony-forming ability and increased γ-H2AX foci formation in A549/GR cells, indicating that CXCR4-mediated STAT3 signaling plays an important role for IR resistance in NSCLC cells. Finally, CXCR4/STAT3 signaling was mediated with the upregulation of Slug and downregulation of the same with siRNA, which heightened IR sensitivity in NSCLC cells. Our data collectively suggests that CXCR4/STAT3/Slug axis is paramount for IR resistance of NSCLC cells, and can be regarded as a therapeutic target to enhance the IR sensitivity of this devastating cancer.

Details

Title
CXCR4 uses STAT3-mediated slug expression to maintain radioresistance of non-small cell lung cancer cells: emerges as a potential prognostic biomarker for lung cancer
Author
Jeong-Yub, Kim 1 ; Hee-Jin, Kim 2 ; Chan-Woong, Jung 3 ; Lee, Tae Sup 4   VIAFID ORCID Logo  ; Kim Eun Ho 5 ; Myung-Jin, Park 1   VIAFID ORCID Logo 

 Korea Institute of Radiological and Medical Sciences, Radiation Therapeutics Development Team, Division of Radiation Cancer Science, Seoul, Korea (GRID:grid.415464.6) (ISNI:0000 0000 9489 1588) 
 Korea Institute of Radiological and Medical Sciences, Radiation Therapeutics Development Team, Division of Radiation Cancer Science, Seoul, Korea (GRID:grid.415464.6) (ISNI:0000 0000 9489 1588); Korea University, School of Biomedical Science, Seoul, Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678) 
 Korea Institute of Radiological and Medical Sciences, Radiation Therapeutics Development Team, Division of Radiation Cancer Science, Seoul, Korea (GRID:grid.415464.6) (ISNI:0000 0000 9489 1588); Korea University, Department of Life Sciences, Seoul, Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678) 
 Korea Institute of Radiological and Medical Sciences, Division of RI Application, Seoul, Korea (GRID:grid.415464.6) (ISNI:0000 0000 9489 1588) 
 Daegu Catholic University, Department of Biochemistry, School of Medicine, Daegu, Korea (GRID:grid.412072.2) (ISNI:0000 0004 0621 4958) 
Publication year
2021
Publication date
Jan 2021
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2476049619
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.